The National Organization for Rare Disorders (NORD) is a non-profit organization that provides information, programs, and services for thousands of rare medical conditions, including primary immunodeficiencies. NORD's RareCare® Patient Assistance Program offers more than 100 opportunities for financial aid to pay for the medical care you need and to help you through emergency situations.

The National Organization for Rare Disorders (NORD) is a non-profit organization that provides information, programs, and services for thousands of rare medical conditions, including primary immunodeficiencies.

NeedyMeds is a 501(c)(3) national non-profit that connects people to programs that will help them afford their medications and other healthcare costs.

The Partnership for Prescription Assistance brings together America’s pharmaceutical companies, doctors, other healthcare providers, patient advocacy organizations, and community groups to help qualifying patients who lack prescription coverage get the medicines they need through the public or private program that’s right for them.

Led by the Plasma Protein Therapeutics Association (PPTA), the Patient Notification System was developed by the manufacturers of plasma therapies with direct input from consumers. The Patient Notification System is a free, confidential, quick communication system providing information on withdrawals and recalls.

Patient assistance programs are run by pharmaceutical companies to provide free medications to people who cannot afford to buy their medicine. RxAssist offers a comprehensive database of these patient assistance programs, as well as practical tools, news, and articles so that healthcare professionals and patients can find the information they need.

Save Babies Through Screening Foundation educates parents, pediatric healthcare providers, and policy makers about available comprehensive newborn screening.

We provide free commercial flights to children and their families in need of life-changing medical care not found in their communities.